Scinopharm Taiwan, Ltd. 2017 Annual Report
Total Page:16
File Type:pdf, Size:1020Kb
Stock Code:1789 ScinoPharm Taiwan, Ltd. 2017 Annual Report Notice to readers This English-version annual report is a summary translation of the Chinese version and is not an official document of the shareholders’ meeting. If there is any discrepancy between the English and Chinese versions, the Chinese version shall prevail. Taiwan Stock Exchange Market Observation Post System: http://mops.twse.com.tw ScinoPharm Taiwan, Ltd. Annual Report is available at: http://www.scinopharm.com.tw Printed on 04 30, 2018 Spokesperson Headquarters, Branches and Plant Name: To be determined by the BOD Headquarters Title: To be determined by the BOD Address: No.1, Nan-Ke 8th Road Tel: 886-6-5052888 Southern Taiwan Science Park E-mail: To be determined by the BOD Shan-Hua, Tainan, 74144, Taiwan Tel: 886-6-5052888 Deputy Spokesperson Name: Chih-Hui Lin Title: Director of Finance Tel: 886-6-5052888 E-mail:[email protected] Stock Transfer Agent President Securities Corporation Address: B1, No.8, Dongxing Rd., Taipei City Tel: 886-2-2746-3797 Website: Http://www.pscnet.com.tw Auditors PricewaterhouseCoopers, Taiwan Address: 12F, 395 Linsen Rd., Sec. 1 Tainan, Taiwan 70151 Tel.: 886-6-234-3111 Website: http://www.pwc.tw/ Overseas Securities Exchange Not applicable Corporate Website http://www.scinopharm.com.tw II Contents I Letter to Shareholders .............................................................................................. 1 II. Company Profile ..................................................................................................... 4 2.1 Date of Incorporation ............................................................................................................ 4 2.2 Company History................................................................................................................... 4 III. Corporate Governance Report ............................................................................ 7 3.1 Organization .......................................................................................................................... 7 3.2 Directors, Supervisors and Management Team ................................................................... 10 3.3 Remuneration paid to Company directors, supervisors, president, and senior vice presidents over the past year .............................................................................................. 25 3.4 Implementation of Corporate Governance .......................................................................... 30 3.5 Information Regarding the Company’s Audit Fee and Independence ................................ 81 3.6 Replacement of CPA ........................................................................................................... 81 3.7 If the Company's Chairman, President, or managers responsible for financial and accounting affairs have held any position in the accounting firm or its affiliates during the past year, all relevant information should be disclosed .................................... 82 3.8 Net Change in shareholdings and in shares pledged by directors, supervisors, management, and shareholders holding more than a 10% share in the Company ............. 82 3.9 Relationship among the Top Ten Shareholders................................................................... 84 3.10 Ownership of Shares in Affiliated Enterprises ................................................................ 100 IV. Capital Overview ............................................................................................... 101 4.1 Capital and Shares ............................................................................................................. 101 4.2 Bonds ................................................................................................................................. 106 4.3 Status of Corporate Bonds, Preferred Stock, GDR, Employee Stock Option Plan, Employee Restricted Stock Plans, Mergers, Acquisitions, and Spin-Offs ....................... 107 4.4 Financing Plans and Implementation ................................................................................ 109 V. Operational Highlights ....................................................................................... 110 5.1 Business Activities ............................................................................................................ 110 5.2 Market and Sales Overview............................................................................................... 128 5.3 Human Resources .............................................................................................................. 142 5.4 Environmental Protection Expenditure ............................................................................. 142 5.5 Protective measures for workplace and personal safety of employees ............................. 147 5.6 Labor Relations ................................................................................................................. 151 5.7 Important Contracts ........................................................................................................... 155 VI. Financial Information ....................................................................................... 158 6.1 Five-Year Financial Summary .......................................................................................... 158 III 6.2 Five-Year Financial Analysis ............................................................................................ 163 6.3Audit Committee’s Report in the Most Recent Year ......................................................... 169 6.4 The Audited Consolidated Financial Report for the most Recent Fiscal Year ................. 169 6.5 The Audited Parent Company only Financial Report for the most Recent Fiscal Year .................................................................................................................................. 169 6.6 Financial Difficulties ......................................................................................................... 169 VII Review of Financial Conditions, Operating Results, and Risk Management ..................................................................................................... 170 7.1 Analysis of Financial Status .............................................................................................. 170 7.2 Analysis of Operation Results ........................................................................................... 171 7.3 Analysis of Cash Flow....................................................................................................... 173 7.4 Major Capital Expendure Items......................................................................................... 174 7.5 Investment Policy in Last Year, Main Causes for Profits or Losses, Improvement Plans and the Investment Plans for the Coming Year ...................................................... 174 7.6 Analysis of Risk Management........................................................................................... 176 7.7 Other Important Matters .................................................................................................... 184 VIII.Special Disclosure ............................................................................................ 185 8.1 Summary of Affiliated Companies .................................................................................... 185 8.2 Private Placement Securities in the Most Recent Years .................................................... 195 8.3 The Shares in the Company Held or Disposed of by Subsidiaries in the Most Recent Years .................................................................................................................... 195 8.4 Other Necessary Supplement ............................................................................................ 195 8.5 Other Supplementary Disclosure ....................................................................................... 197 IV I Letter to Shareholders Dear Shareholders: In recent years, low prices have hit the generic drug market globally and the merging of companies has become a trend. In the United States, many mergers and acquisitions in the pharmaceutical retail channel have led to depressed prices from joint procurements. At the same time, oncology drugs are being seen as personalized medical treatment. Fewer small molecule blockbuster drugs are found in the market. Coupled with the strong appreciation of the Taiwan dollar over the last year, these phenomena have impacted the annual profit and revenue of export-oriented ScinoPharm. Despite the intensifying external environmental challenges, with the concerted diligence of its employees, ScinoPharm has employed continuous effort in optimizing processes, controlling costs and increasing management efficiency. At the same time, it has also been accelerating the expansion of product lines, making good use of active pharmaceutical ingredient into the development of formulated products, and proactively making headway into the field of specialty generic drug development. In 2017, the company’s consolidated annual revenue was NT$3.516 billion. The after-tax net profit was NT$422 million, and the after-tax earnings per share was NT$0.53. As of the end of last year, the company’s paid-up capital was NT$7.907 billion, and the shareholder’s equity was NT$10.4 billion, which accounted for approximately 82% of its total assets